Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
UHCs 2026 commercial formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda (liraglutide for obesity), and Rybelsus (oral semaglutide for type 2 diabetes)
Semaglutide does not burn fat directly
However, its unsuitable for individuals with a personal or family history of medullary thyroid carcinoma or MEN syndrome type 2
Vitamin B12 or folate deficiency anaemia - Complications
There is no quality assurance, no batch testing to pharmaceutical standards, and no clinical oversight when you are administering them on your own
,type=downsize)
US$ 21.14
US$ 22.47
US$ 23.76
US$ 20.54
US$ 28.38
US$ 27.26
US$ 23.20
US$ 22.69
US$ 21.59
US$ 27.35
US$ 29.79
US$ 23.91
US$ 21.06
